Logotyp: till Uppsala universitets webbplats

uu.sePublikationer från Uppsala universitet
Ändra sökning
Länk till posten
Permanent länk

Direktlänk
Alternativa namn
Publikationer (10 of 85) Visa alla publikationer
Niklasson, M., Dalmo, E., Segerman, A., Rendo, V. & Westermark, B. (2025). p21-Dependent Senescence Induction by BMP4 Renders Glioblastoma Cells Vulnerable to Senolytics. International Journal of Molecular Sciences, 26(9), Article ID 3974.
Öppna denna publikation i ny flik eller fönster >>p21-Dependent Senescence Induction by BMP4 Renders Glioblastoma Cells Vulnerable to Senolytics
Visa övriga...
2025 (Engelska)Ingår i: International Journal of Molecular Sciences, ISSN 1661-6596, E-ISSN 1422-0067, Vol. 26, nr 9, artikel-id 3974Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Glioblastoma (GBM) is a highly malignant brain tumor with extensive cellular heterogeneity and plasticity. Bone morphogenetic protein 4 (BMP4) has shown potential as a therapeutic agent by promoting differentiation, but its effects are complex and context dependent. While BMP4's role in differentiation is well established, its impact on senescence remains unclear. This study investigates BMP4's ability to induce senescence in GBM cells. Primary GBM cultures were treated with BMP4 and analyzed for senescence markers, including cell enlargement, p21 expression, senescence-related gene enrichment, and senescence-associated-beta-galactosidase activity. A p21 knockout model was used to determine its role in BMP4-induced senescence, and sensitivity to the senolytic agent navitoclax was evaluated. BMP4 induced senescence in the GBM cultures, particularly in mesenchymal (MES)-like GBM cells with high baseline p21 levels. The knockout of p21 nearly abolished BMP4-induced senescence, maintaining cell size and proliferation. Furthermore, navitoclax effectively eliminated BMP4-induced senescent cells through apoptosis, while sparing cells with normal p21 expression. Our findings highlight BMP4 as an inducer of p21-dependent senescence in GBM, particularly in MES-like cells. This study clarifies BMP4's dual roles in differentiation and senescence, emphasizing their context dependence. Given the strong link between MES-like cells and therapy resistance, their heightened susceptibility to senescence may aid in developing targeted therapies for GBM and potentially other cancers with similar cellular dynamics.

Ort, förlag, år, upplaga, sidor
MDPI, 2025
Nyckelord
glioblastoma, senescence, BMP4, mesenchymal transition, p21
Nationell ämneskategori
Cancer och onkologi Cell- och molekylärbiologi
Identifikatorer
urn:nbn:se:uu:diva-557084 (URN)10.3390/ijms26093974 (DOI)001486427900001 ()40362216 (PubMedID)2-s2.0-105004918957 (Scopus ID)
Forskningsfinansiär
Cancerfonden, 20 1020 PjF 01 HVetenskapsrådet, 2017-01564Cancerfonden, 22 2209 Pj 01 H
Tillgänglig från: 2025-05-23 Skapad: 2025-05-23 Senast uppdaterad: 2025-05-23Bibliografiskt granskad
Westermark, B. & Heldin, C.-H. (2024). Special issue: frontiers in recent advances on cancer diagnosis and treatment. Upsala Journal of Medical Sciences, 129, Article ID e11919.
Öppna denna publikation i ny flik eller fönster >>Special issue: frontiers in recent advances on cancer diagnosis and treatment
2024 (Engelska)Ingår i: Upsala Journal of Medical Sciences, ISSN 0300-9734, E-ISSN 2000-1967, Vol. 129, artikel-id e11919Artikel i tidskrift, Editorial material (Övrigt vetenskapligt) Published
Ort, förlag, år, upplaga, sidor
Upsala Medical Society, 2024
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:uu:diva-550028 (URN)10.48101/ujms.v129.11919 (DOI)001399023300001 ()39780954 (PubMedID)2-s2.0-85214353252 (Scopus ID)
Tillgänglig från: 2025-02-11 Skapad: 2025-02-11 Senast uppdaterad: 2025-02-11Bibliografiskt granskad
Gupta, R. K., Niklasson, M., Bergström, T., Segerman, A., Betsholtz, C. & Westermark, B. (2024). Tumor-specific migration routes of xenotransplanted human glioblastoma cells in mouse brain. Scientific Reports, 14, Article ID 864.
Öppna denna publikation i ny flik eller fönster >>Tumor-specific migration routes of xenotransplanted human glioblastoma cells in mouse brain
Visa övriga...
2024 (Engelska)Ingår i: Scientific Reports, E-ISSN 2045-2322, Vol. 14, artikel-id 864Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

The migration of neural progenitor cells (NPCs) to their final destination during development follows well-defined pathways, such as along blood vessels. Cells originating from the highly malignant tumor glioblastoma (GBM) seem to exploit similar routes for infiltrating the brain parenchyma. In this report, we have examined the migration of GBM cells using three-dimensional high-resolution confocal microscopy in brain tumors derived from eight different human GBM cell lines xenografted into immunodeficient mice. The primary invasion routes identified were long-distance migration along white matter tracts and local migration along blood vessels. We found that GBM cells in the majority of tumors (6 out of 8) did not exhibit association with blood vessels. These tumors, derived from low lamin A/C expressing GBM cells, were comparatively highly diffusive and invasive. Conversely, in 2 out of 8 tumors, we noted perivascular invasion and displacement of astrocyte end-feet. These tumors exhibited less diffusive migration, grew as solid tumors, and were distinguished by elevated expression of lamin A/C. We conclude that the migration pattern of glioblastoma is distinctly tumor cell-specific. Furthermore, the ability to invade the confined spaces within white matter tracts may necessitate low expression of lamin A/C, contributing to increased nuclear plasticity. This study highlights the role of GBM heterogeneity in driving the aggressive growth of glioblastoma.

Ort, förlag, år, upplaga, sidor
Springer Nature, 2024
Nationell ämneskategori
Cancer och onkologi Cell- och molekylärbiologi
Identifikatorer
urn:nbn:se:uu:diva-522882 (URN)10.1038/s41598-023-51063-7 (DOI)001139656300036 ()38195678 (PubMedID)
Forskningsfinansiär
Cancerfonden
Tillgänglig från: 2024-02-12 Skapad: 2024-02-12 Senast uppdaterad: 2024-02-12Bibliografiskt granskad
Ilkhanizadeh, S., Gracias, A., Aslund, A. K. O., Back, M., Simon, R., Kavanagh, E., . . . Nilsson, K. P. (2023). Live Detection of Neural Progenitors and Glioblastoma Cells by an Oligothiophene Derivative. ACS Applied Bio Materials, 6(9), 3790-3797
Öppna denna publikation i ny flik eller fönster >>Live Detection of Neural Progenitors and Glioblastoma Cells by an Oligothiophene Derivative
Visa övriga...
2023 (Engelska)Ingår i: ACS Applied Bio Materials, E-ISSN 2576-6422, Vol. 6, nr 9, s. 3790-3797Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

There is an urgent need for simple and non-invasive identification of live neural stem/progenitor cells (NSPCs) in the developing and adult brain as well as in disease, such as in brain tumors, due to the potential clinical importance in prognosis, diagnosis, and treatment of diseases of the nervous system. Here, we report a luminescent conjugated oligothiophene (LCO), named p-HTMI, for non-invasive and non-amplified real-time detection of live human patient-derived glioblastoma (GBM) stem cell-like cells and NSPCs. While p-HTMI stained only a small fraction of other cell types investigated, the mere addition of p-HTMI to the cell culture resulted in efficient detection of NSPCs or GBM cells from rodents and humans within minutes. p-HTMI is functionalized with a methylated imidazole moiety resembling the side chain of histidine/histamine, and non-methylated analogues were not functional. Cell sorting experiments of human GBM cells demonstrated that p-HTMI labeled the same cell population as CD271, a proposed marker for stem cell-like cells and rapidly migrating cells in glioblastoma. Our results suggest that the LCO p-HTMI is a versatile tool for immediate and selective detection of neural and glioma stem and progenitor cells.

Ort, förlag, år, upplaga, sidor
American Chemical Society (ACS), 2023
Nyckelord
bioelectronics, progenitor, brain tumor, methylation, p75NTR
Nationell ämneskategori
Cancer och onkologi Neurovetenskaper Cell- och molekylärbiologi
Identifikatorer
urn:nbn:se:uu:diva-519795 (URN)10.1021/acsabm.3c00447 (DOI)001064987700001 ()37647213 (PubMedID)
Forskningsfinansiär
CancerfondenKnut och Alice Wallenbergs StiftelseStiftelsen för strategisk forskning (SSF)EU, Europeiska forskningsrådetVinnovaVetenskapsrådet
Tillgänglig från: 2024-01-10 Skapad: 2024-01-10 Senast uppdaterad: 2024-01-10Bibliografiskt granskad
Ramachandran, M., Vaccaro, A., van de Walle, T., Georganaki, M., Lugano, R., Vemuri, K., . . . Dimberg, A. (2023). Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell, 41(6), 1134-1151
Öppna denna publikation i ny flik eller fönster >>Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
Visa övriga...
2023 (Engelska)Ingår i: Cancer Cell, ISSN 1535-6108, E-ISSN 1878-3686, Vol. 41, nr 6, s. 1134-1151Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Glioblastomas are aggressive brain tumors that are largely immunotherapy resistant. This is associated with immunosuppression and a dysfunctional tumor vasculature, which hinder T cell infiltration. LIGHT/TNFSF14 can induce high endothelial venules (HEVs) and tertiary lymphoid structures (TLS), suggesting that its therapeutic expression could promote T cell recruitment. Here, we use a brain endothelial cell-targeted ad-eno-associated viral (AAV) vector to express LIGHT in the glioma vasculature (AAV-LIGHT). We found that systemic AAV-LIGHT treatment induces tumor-associated HEVs and T cell-rich TLS, prolonging survival in aPD-1-resistant murine glioma. AAV-LIGHT treatment reduces T cell exhaustion and promotes TCF1+CD8+ stem-like T cells, which reside in TLS and intratumoral antigen-presenting niches. Tumor regres-sion upon AAV-LIGHT therapy correlates with tumor-specific cytotoxic/memory T cell responses. Our work reveals that altering vascular phenotype through vessel-targeted expression of LIGHT promotes efficient anti-tumor T cell responses and prolongs survival in glioma. These findings have broader implications for treatment of other immunotherapy-resistant cancers.

Ort, förlag, år, upplaga, sidor
ElsevierElsevier BV, 2023
Nyckelord
glioblastoma, TNFSF14, LIGHT, lymphotoxin αβ, tertiary lymphoid structures, stem-like T cells, high endothelial venules, antigen-presenting niches
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
urn:nbn:se:uu:diva-508441 (URN)10.1016/j.ccell.2023.04.010 (DOI)001025445800001 ()37172581 (PubMedID)
Forskningsfinansiär
Cancerfonden, CAN 2017/502Cancerfonden, 20 1008 PjFCancerfonden, 201010 UsFCancerfonden, 190184PjVetenskapsrådet, 2016-02495Vetenskapsrådet, 2020-02563Vetenskapsrådet, 2019-01326Knut och Alice Wallenbergs Stiftelse, KAW 2019.0088Barncancerfonden, TJ 2019-0014Cancerfonden, CAN 2015/1216
Tillgänglig från: 2023-08-02 Skapad: 2023-08-02 Senast uppdaterad: 2025-03-27Bibliografiskt granskad
Liu, J., He, L., Muhl, L., Mocci, G., Gustavsson, S., Buyandelger, B., . . . Andrae, J. (2021). A human cell type similar to murine central nervous system perivascular fibroblasts. Experimental Cell Research, 402(2), Article ID 112576.
Öppna denna publikation i ny flik eller fönster >>A human cell type similar to murine central nervous system perivascular fibroblasts
Visa övriga...
2021 (Engelska)Ingår i: Experimental Cell Research, ISSN 0014-4827, E-ISSN 1090-2422, Vol. 402, nr 2, artikel-id 112576Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

The brain vasculature has several specific features, one of them being the blood-brain barrier (BBB), which supports and protects the brain by allowing for the passage of oxygen and nutrients, while at the same time preventing passage of pathogens and toxins. The BBB also prevents efficient delivery of drugs to the brain, e.g. for treatment of brain tumors. In the murine brain, perivascular fibroblasts were recently identified as a novel potential constituent of the BBB. Here we present the existence of human cells that could be the equivalent to the murine brain perivascular fibroblasts. Using RNA sequencing, we show a similar transcriptomic profile of cultured human brain cells and murine perivascular fibroblasts. These data open up a window for new hypotheses on cell types involved in human CNS diseases.

Ort, förlag, år, upplaga, sidor
ElsevierELSEVIER INC, 2021
Nyckelord
Human, Murine, Brain, Perivascular, Fibroblast, RNA sequencing
Nationell ämneskategori
Cell- och molekylärbiologi
Identifikatorer
urn:nbn:se:uu:diva-443075 (URN)10.1016/j.yexcr.2021.112576 (DOI)000640393900005 ()33798592 (PubMedID)
Forskningsfinansiär
Vetenskapsrådet, 2015-00550Cancerfonden, 150735Knut och Alice Wallenbergs Stiftelse, 2015.0030
Tillgänglig från: 2021-05-28 Skapad: 2021-05-28 Senast uppdaterad: 2024-01-15Bibliografiskt granskad
Larsson, I., Lundin, E., Elgendy, R., Niklasson, M., Doroszko, M., Segerman, A., . . . Nelander, S. (2021). Modeling glioblastoma heterogeneity as a dynamic network of cell states. Molecular Systems Biology, 17(9), Article ID e10105.
Öppna denna publikation i ny flik eller fönster >>Modeling glioblastoma heterogeneity as a dynamic network of cell states
Visa övriga...
2021 (Engelska)Ingår i: Molecular Systems Biology, ISSN 1744-4292, E-ISSN 1744-4292, Vol. 17, nr 9, artikel-id e10105Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Tumor cell heterogeneity is a crucial characteristic of malignant brain tumors and underpins phenomena such as therapy resistance and tumor recurrence. Advances in single-cell analysis have enabled the delineation of distinct cellular states of brain tumor cells, but the time-dependent changes in such states remain poorly understood. Here, we construct quantitative models of the time-dependent transcriptional variation of patient-derived glioblastoma (GBM) cells. We build the models by sampling and profiling barcoded GBM cells and their progeny over the course of 3 weeks and by fitting a mathematical model to estimate changes in GBM cell states and their growth rates. Our model suggests a hierarchical yet plastic organization of GBM, where the rates and patterns of cell state switching are partly patient-specific. Therapeutic interventions produce complex dynamic effects, including inhibition of specific states and altered differentiation. Our method provides a general strategy to uncover time-dependent changes in cancer cells and offers a way to evaluate and predict how therapy affects cell state composition.

Ort, förlag, år, upplaga, sidor
John Wiley & SonsWILEY, 2021
Nyckelord
cell state, cellular barcoding, patient-derived brain tumor cells, single-cell lineage tracing, time-dependent computational models
Nationell ämneskategori
Cellbiologi Cell- och molekylärbiologi
Identifikatorer
urn:nbn:se:uu:diva-466275 (URN)10.15252/msb.202010105 (DOI)000700839700005 ()34528760 (PubMedID)
Forskningsfinansiär
CancerfondenVetenskapsrådetStiftelsen för strategisk forskning (SSF)
Tillgänglig från: 2022-01-26 Skapad: 2022-01-26 Senast uppdaterad: 2024-01-15Bibliografiskt granskad
Larsson, I., Dalmo, E., Elgendy, R., Niklasson, M., Doroszko, M., Segerman, A., . . . Nelander, S. (2021). Modeling glioblastoma heterogeneity as a dynamic network of cell states. Molecular Systems Biology, 17(9), Article ID MSB202010105.
Öppna denna publikation i ny flik eller fönster >>Modeling glioblastoma heterogeneity as a dynamic network of cell states
Visa övriga...
2021 (Engelska)Ingår i: Molecular Systems Biology, E-ISSN 1744-4292, Vol. 17, nr 9, artikel-id MSB202010105Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Tumor cell heterogeneity is a crucial characteristic of malignant brain tumors and underpins phenomena such as therapy resistance and tumor recurrence. Advances in single-cell analysis have enabled the delineation of distinct cellular states of brain tumor cells, but the time-dependent changes in such states remain poorly understood. Here, we construct quantitative models of the time-dependent transcriptional variation of patient-derived glioblastoma (GBM) cells. We build the models by sampling and profiling barcoded GBM cells and their progeny over the course of 3 weeks and by fitting a mathematical model to estimate changes in GBM cell states and their growth rates. Our model suggests a hierarchical yet plastic organization of GBM, where the rates and patterns of cell state switching are partly patient-specific. Therapeutic interventions produce complex dynamic effects, including inhibition of specific states and altered differentiation. Our method provides a general strategy to uncover time-dependent changes in cancer cells and offers a way to evaluate and predict how therapy affects cell state composition.

Ort, förlag, år, upplaga, sidor
Springer Nature, 2021
Nyckelord
cell state, cellular barcoding, patient-derived brain tumor cells, single-cell lineage tracing, time-dependent computational models
Nationell ämneskategori
Cellbiologi Cell- och molekylärbiologi
Identifikatorer
urn:nbn:se:uu:diva-495138 (URN)10.15252/msb.202010105 (DOI)000700839700005 ()34528760 (PubMedID)
Forskningsfinansiär
CancerfondenVetenskapsrådetStiftelsen för strategisk forskning (SSF)BarncancerfondenUppsala universitet
Anmärkning

De två första författarna delar förstaförfattarskapet.

De två sista författarna delar sistaförfattarskapet.

Tillgänglig från: 2023-01-24 Skapad: 2023-01-24 Senast uppdaterad: 2026-04-28Bibliografiskt granskad
Dalmo, E., Johansson, P., Niklasson, M., Gustavsson, I., Nelander, S. & Westermark, B. (2020). Growth-Inhibitory Activity of Bone Morphogenetic Protein 4 in Human Glioblastoma Cell Lines Is Heterogeneous and Dependent on Reduced SOX2 Expression. Molecular Cancer Research, 18(7), 981-991
Öppna denna publikation i ny flik eller fönster >>Growth-Inhibitory Activity of Bone Morphogenetic Protein 4 in Human Glioblastoma Cell Lines Is Heterogeneous and Dependent on Reduced SOX2 Expression
Visa övriga...
2020 (Engelska)Ingår i: Molecular Cancer Research, ISSN 1541-7786, E-ISSN 1557-3125, Vol. 18, nr 7, s. 981-991Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Glioblastoma multiforme continues to have a dismal prognosis. Even though detailed information on the genetic aberrations in cell signaling and cell-cycle checkpoint control is available, no effective targeted treatment has been developed. Despite the advanced molecular defects, glioblastoma cells may have remnants of normal growth-inhibitory pathways, such as the bone morphogenetic protein (BMP) signaling pathway. We have evaluated the growth-inhibitory effect of BMP4 across a broad spectrum of patient samples, using a panel of 40 human glioblastoma initiating cell (GIC) cultures. A wide range of responsiveness was observed. BMP4 sensitivity was positively correlated with a proneural mRNA expression profile, high SOX2 activity, and BMP4-dependent upregulation of genes associated with inhibition of the MAPK pathway, as demonstrated by gene set enrichment analysis. BMP4 response in sensitive cells was mediated by the canonical BMP receptor pathway involving SMAD1/5/9 phosphorylation and SMAD4 expression. SOX2 was consistently downregulated in BMP4-treated cells. Forced expression of SOX2 attenuated the BMP4 sensitivity including a reduced upregulation of MAPK-inhibitory genes, implying a functional relationship between SOX2 downregulation and sensitivity. The results show an extensive heterogeneity in BMP4 responsiveness among GICs and identify a BMP4-sensitive subgroup, in which SOX2 is a mediator of the response.

Nationell ämneskategori
Cell- och molekylärbiologi
Identifikatorer
urn:nbn:se:uu:diva-419943 (URN)10.1158/1541-7786.MCR-19-0638 (DOI)000546016600004 ()32234828 (PubMedID)
Forskningsfinansiär
Vetenskapsrådet, 2018-02699Cancerfonden, 18 0528Cancerfonden, 17 0704Stiftelsen för strategisk forskning (SSF), SB16-0066Knut och Alice Wallenbergs Stiftelse
Tillgänglig från: 2020-09-21 Skapad: 2020-09-21 Senast uppdaterad: 2023-01-27Bibliografiskt granskad
Cancer, M., Drews, L. F., Bengtsson, J., Bolin, S., Rosén, G., Westermark, B., . . . Johansson, F. K. (2019). BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells. Cell Death and Disease, 10, Article ID 881.
Öppna denna publikation i ny flik eller fönster >>BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells
Visa övriga...
2019 (Engelska)Ingår i: Cell Death and Disease, E-ISSN 2041-4889, Vol. 10, artikel-id 881Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Patients usually undergo surgery followed by aggressive radio- and chemotherapy with the alkylating agent temozolomide (TMZ). Still, median survival is only 12-15 months after diagnosis. Many human cancers including GBMs demonstrate addiction to MYC transcription factor signaling and can become susceptible to inhibition of MYC downstream genes. JQ1 is an effective inhibitor of BET Bromodomains, a class of epigenetic readers regulating expression of downstream MYC targets. Here, we show that BET inhibition decreases viability of patient-derived GBM cell lines. We propose a distinct expression signature of MYCN-elevated GBM cells that correlates with significant sensitivity to BET inhibition. In tumors showing JQ1 sensitivity, we found enrichment of pathways regulating cell cycle, DNA damage response and repair. As DNA repair leads to acquired chemoresistance to TMZ, JQ1 treatment in combination with TMZ synergistically inhibited proliferation of MYCN-elevated cells. Bioinformatic analyses further showed that the expression of MYCN correlates with Aurora Kinase A levels and Aurora Kinase inhibitors indeed showed synergistic efficacy in combination with BET inhibition. Collectively, our data suggest that BET inhibitors could potentiate the efficacy of either TMZ or Aurora Kinase inhibitors in GBM treatment.

Ort, förlag, år, upplaga, sidor
NATURE PUBLISHING GROUP, 2019
Nationell ämneskategori
Cancer och onkologi Cellbiologi
Identifikatorer
urn:nbn:se:uu:diva-398423 (URN)10.1038/s41419-019-2120-1 (DOI)000497973200005 ()31754113 (PubMedID)
Forskningsfinansiär
CancerfondenVetenskapsrådetSvenska läkaresällskapetRagnar Söderbergs stiftelseBarncancerfondenScience for Life Laboratory - a national resource center for high-throughput molecular bioscience
Tillgänglig från: 2019-12-06 Skapad: 2019-12-06 Senast uppdaterad: 2024-07-04Bibliografiskt granskad
Organisationer
Identifikatorer
ORCID-id: ORCID iD iconorcid.org/0000-0001-7153-5545

Sök vidare i DiVA

Visa alla publikationer